New Market Perspective
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

New Market Perspective

Investing

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

by admin November 18, 2024
November 18, 2024
ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

  • All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of Island’s ISLA-101 Phase 2a/b PROTECT clinical trial in dengue fever
  • Data currently being consolidated for review by the Safety Review Committee (SRC) in the coming weeks
  • On track to release SRC recommendation on advancing the trial to Phase 2b by end of this calendar year
In Island’s Phase 2a trial, subjects receive ISLA-101 before being infected with a weakened dengue virus developed by the US Army. The trial aims to assess whether ISLA-101 can prevent or reduce viremia and symptoms compared to a placebo, based on previous control data showing elevated viremia and symptoms in untreated subjects.

Following the announcement (ASX: 3 October 2024) that all subjects in the Phase 2a cohort of the trial had been dosed, Island confirms it has now collected the required samples to analyse how the viremia (viral load) levels in the blood of trial subjects have changed through the study. Other samples are being analysed for pharmacokinetic data as well as other blood analyses.

This data is currently being consolidated for review by the Safety Review Committee (SRC), who will meet in the coming weeks. The SRC will evaluate the safety of ISLA-101 in dengue infected individuals and consider if there is evidence of anti-dengue activity. They will then make a recommendation regarding advancing the trial to the Phase 2b cohort before the end of the calendar year.

Island’s CEO and Managing Director, Dr David Foster commented, “We are very pleased to be able to report that 46 days into the trial, we’ve collected the key data required for evaluation by the Safety Review Committee. From here, while we will continue to check in with patients up to 90 days post dosing, we look forward to providing all the data to the SRC for evaluation in the coming weeks. Importantly, this means we remain on track to report data before the end of the year from our Phase 2a component, and next steps for the Phase 2b cohort before the end of the year.”

Phase 2b will include 10 subjects randomised 8:2 (active: placebo) and will examine if ISLA-101 has activity as a treatment against dengue infection. This is the first time a potential countermeasure to combat the dengue virus, which afflicts more than 400 million individuals a year and for which there is no therapeutic option, is being investigated as both a preventative and therapeutic measure.

To subscribe to Island’s monthly newsletter, IslandWatch, and other forms of email communications, please visit this page of our website.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Notice of Initial Substantial Holder – Regal Funds Management Pty Ltd
next post
Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing Nears

Related Posts

Accelerated Non-Renounceable Entitlement Offer Results

December 3, 2024

Eskay Mining and P2 Gold Agree to Merge,...

June 6, 2024

Stunalara Acceptances Reach 54%

March 14, 2025

Silver North

December 27, 2023

Tech 5: Big Tech Players Release Latest Results,...

November 3, 2024

Ewoyaa Lithium Project Granted EPA Permit

September 12, 2024

GMV Minerals Inc. Completes Initial Drilling at Daisy...

September 26, 2024

Michael Campbell: Gold, Uranium, Oil/Gas — Bullish as...

February 3, 2025

Skyharbour Appoints Athabasca Basin Veteran, Serdar Donmez, as...

September 12, 2024

Carbon Done Right Announces Receipt of Fifth Disbursement...

July 24, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • UK police make second arrest in connection with fires linked to PM Starmer

      May 18, 2025
    • Deported mom says toddler’s return to Venezuela after separation by US authorities was a ‘miracle’

      May 18, 2025
    • Duterte scores landslide win in local elections. But can he be mayor from The Hague?

      May 18, 2025
    • Austria’s JJ wins Eurovision 2025 with ‘Wasted Love’

      May 18, 2025
    • How Pope Leo dealt with years of abuse allegations in a powerful Catholic society in Peru

      May 18, 2025
    • The popemobile, a signet ring and a ‘betrothal:’ How Pope Leo’s inauguration will unfold

      May 18, 2025

    Popular

    • 1

      10 Top Oil-producing Countries (Updated 2024)

      October 19, 2024
    • 2

      Powered by rain, this seed carrier could help reforest the most remote areas

      December 19, 2023
    • 3

      A troubling theory about traders profiting from Hamas’ attack on Israel drew much attention. Why it may not be so simple.

      December 13, 2023
    • 4

      Americans are starting to feel better about the economy and inflation

      December 13, 2023
    • 5

      Rare Earths Stocks: 8 Biggest Companies in 2024

      January 12, 2024
    • 6

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024
    • 7

      Investing in Graphene Companies

      May 9, 2024

    Categories

    • Business (1,322)
    • Investing (3,124)
    • Politics (4,105)
    • World (4,057)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: newmarketperspective.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 newmarketperspective.com | All Rights Reserved